Navigation Links
Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Date:6/1/2011

HUNTSVILLE, Ala., June 1, 2011 /PRNewswire/ -- Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD, reported today that Serina has closed on a $9.5 million financing round to advance its lead oncology candidate SER-203 into a Phase I study in humans in early 2012.

"We are pleased to report to our existing and new shareholders the closing of the financing round that was launched in late 2010. This is a very significant milestone for Serina Therapeutics, and will allow us to advance our lead oncology candidate into Phase Ia and continue to build a robust pipeline of novel polymer therapeutics for unmet medical needs," stated Dr. Moreadith.

"Serina's polymer technology has enormous potential to advance novel polymer drugs, not just for oncology but for many diseases including metabolic disorders, pain and inflammation. This capital gives us sufficient resources to advance our first molecule into the clinic, and we wish to express our sincere appreciation to our shareholders."

Serina Therapeutics, Inc. is a private pharmaceutical company located at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., and is the only company in the world to develop polyoxazoline (POZ) polymers for pharmaceutical applications. POZ polymers are multifunctional polymers that can be coupled to known drugs, and in doing so these novel therapeutics have dramatically altered pharmacokinetics. Molecules that normally have short duration times in the body can be converted to molecules with prolonged activity – sometimes as long as weeks. This prolonged half-life in the body may improve the safety and efficacy of the molecule. In addition, Serina has developed technology that allows the resulting polymer drug to be specifically targeted to receptors on the surface of cancer cells, and this approach may be useful for applications outside oncology. For more information please visit www.serinatherapeutics.com.

Media contact : Holly Ralston (256) 508-8954


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):